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Abstract 
Background: The first commercially available bioresorbable scaffold (BRS) had a strut thickness of 
156 microns. As such, it had the potential for delivery challenges and higher thrombogenicity. The aim 
herein, is to evaluate biomechanical performance, pharmacokinetics and vascular healing of a novel 
thin strut (100 µm) sirolimus eluting BRS (MeRes-100, Meril Life Sciences, Gujarat, India) against 
the once clinically used BRS (Absorb BVS, Abbott, Santa Clara, CA) in porcine coronary arteries.
Methods: Following device implantation, angiographic and optical coherence tomography (OCT) 
evaluation were performed at 45, 90, 180 days, 1 year and 2 years. Histological evaluation was per-
formed at 30, 90 and 180 days. 
Results: At 2 years, both lumen (MeRes-100 7.07 ± 1.82 mm2 vs. Absorb BVS 7.57 ± 1.39 mm2, p = NS)  
and scaffold areas (MeRes-100 9.73 ± 1.80 mm2 vs. Absorb BVS 9.67 ± 1.25 mm2, p = NS) were 
comparable between tested and control scaffolds. Also, the late lumen area gain at 2 years was similar in 
both groups tested (MeRes-100 1.03 ± 1.98 mm2 vs. Absorb BVS 0.85 ± 1.56 mm2, p = NS). Histologic 
examination up to 6 months showed comparable healing and inflammation profiles for both devices.
Conclusions: The novel sirolimus-eluting BRS with thinner struts and hybrid cell design showed 
similar biomechanical durability and equivalent inhibition of neointimal proliferation when compared 
to the first-ever Absorb BVS up to 2 years in normal porcine coronary arteries. (Cardiol J XXXX; XX, 
X: xx–xx)
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Introduction
Bioresorbable scaffolds (BRS) acting as 
a transient mechanical support during the arterial 
restorative process had been hoped to provide ad-
ditional benefits over metallic drug-eluting stents 
(DES), such as restoration of the treated arterial 
segments to a more physiological state via return 
of vasomotion and elasticity, and eventually late 
lumen gain [1], translating into tangible reduction 
of long-term adverse effects of percutaneous coro-
nary revascularization [2, 3]. However, the recently 
published 2–3-year results from ABSORB II and 
III trials, have proven otherwise, demonstrating 
an opposite trend toward higher adverse events 
in patients treated with the everolimus-eluting 
Absorb BVS [4, 5]. Since a majority of these un-
toward effects have been noted in small coronary 
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arteries, it is believed that the bulky strut thick-
ness of 156 µm, exceeding nearly twice that of 
a contemporary metallic DES, is responsible for 
poorer deliverability and higher thrombotic and 
restenotic potential of this technology [6]. It is 
known that a correlation between strut thickness 
and flow disturbance exists and translates into 
negative clinical consequences, such as higher 
restenosis and target vessel revascularization 
rates [7]. Large strut thickness also increases flow 
disturbances with separation, stagnation, and reat-
tachment of blood elements, which may affect the 
risk of thrombosis [8]. It is therefore imperative 
for the mainstream success of BRS that the strut 
thickness be reduced, resulting in no adverse effect 
on biomechanics. 
In this particular study, the aim was to evaluate 
such an example by assessing biomechanical per-
formance, pharmacokinetics and vascular healing 
of a novel thin strut sirolimus-eluting poly-L-lactic 
acid (PLLA) based BRS with hybrid cell design 
(MeRes-100, Meril Life Sciences, Gujarat, India) in 
comparison to the Absorb BVS (version 1.1, Abbott 
Vascular, Santa Clara, CA).
Methods 
Device description
The MeRes-100 is a thin strut (~100 µm) bal-
loon expandable bioresorbable scaffold comprised 
of a PLLA backbone and topcoat of poly-DL-lactic 
acid (PDLLA) and sirolimus at the 1:1 ratio result-
ing in 1.25 µg/mm2 (Fig. 1). In the current study, 
thin strut MeRes-100 BRS was compared to the 
once commercially available everolimus eluting 
Absorb BVS with strut thickness of 156 µm. The 
device sizes used in the study were as follows: 
MeRes-100 (3.0 × 13, 3.5 × 13, 3.0 × 18 and 
3.5 × 18 mm) and Absorb (sizes 3.0 × 12, 3.5 × 12, 
3.0 × 18 and 3.5 × 18 mm). 
In vivo biomechanical performance  
and healing studies 
The Institutional Animal Care and Use Com-
mittee approved this study, and all animals received 
care in accordance with the Guide for the Care and 
Use of Laboratory Animals. 
To evaluate the healing response of the 
MeRes-100 in direct comparison to Absorb BVS, 
histological analysis was performed in a group of 
6 young adult Yucatan minipigs sacrificed at 30, 
90 and 180 days. Therefore, in total 9 MeRes-100 
(n = 3 per timepoint) and 6 Absorb (n = 2 per time-
point) scaffolds were implanted in 6 animals among 
all three coronary arteries at the overstretch ratio 
of 1.1:1, and the implant location was determined 
by the size of coronary arteries. Mean vessel di-
ameters were measured by quantitative coronary 
analysis to guide sizing of the devices. 
Long term biomechanical performance using 
serial angiography and optical coherence tomo-
graphy (OCT) measurements was evaluated in 
a second group of 5 young adult Yucatan minipigs in 
which a total of n = 9 MeRes-100 and n = 4 Ab-
sorb BVS were implanted. The continuous imaging 
was performed in all animals immediately after 
implantation, at 45, 90, 180 days, 1 and 2 years. 
All 5 animals survived beyond 2 years for ongoing 
Hybrid cell design
Scaffold backbone, PLLA 
100 µm strut thickness
Closed 
cell
Open 
cell
Couplets of tri-axial RO 
markets at either end
Figure 1. Closed cell-open cell hybrid architecture of MeRes-100 scaffold. The scaffold backbone design features 
a repeated, alternatingly oriented zigzag crowns connected by longitudinal links with a hybrid cell design comprised 
of a mix of closed cells at the edges and open cells along the length in order to provide optimal radial strength and 
uncompromised side branch access (open cells in the middle) without worsening flexibility, allowing strut thickness 
of ~100 μm; PLLA — poly-L-lactic acid.
2 www.cardiologyjournal.org
Cardiology Journal XXXX, Vol. XX, No. X
imaging evaluation  The device implantation was 
performed with standard percutaneous technique 
utilizing heparin for anticoagulation. Oral clopi-
dogrel and acetylsalicylic acid was initiated the 
day prior to the procedure and were maintained 
throughout the study. 
In vivo pharmacokinetic study 
The pharmacokinetic profile of MeRes-100 
(n = 10) at 30, 90 and 180 days was evaluated 
using the liquid chromatography mass spectrom-
etry (LCMS/MS), method on file at Agilux Labs 
(Natick, Massachusetts). Briefly, scaffolds were 
extracted in organic solvents. Prior to extraction, 
tissue samples were prepared by dicing followed by 
homogenization in buffer. Sirolimus in the arterial 
tissue extracts was analyzed by LC-MS/MS using 
ascomycin as the internal standard.  Quantitation 
was performed versus a calibration curve and the 
lower limit of quantitation was 50 ng/mL. Siroli-
mus was analyzed in whole blood using protein 
precipitation followed by a solid phase extraction 
procedure and analysis by LC-MS/MS. Quantita-
tion was performed versus a calibration curve and 
the lower limit of quantitation was 0.500 ng/mL. 
The percentage of drug released from the scaffold 
at each time point was determined by measuring 
the residual total content on the explanted stents. 
The sirolimus concentration in whole blood was 
evaluated in 6 pigs bearing 17 MeRes-100 scaffolds. 
Blood samples were collected at 1, 30 min, 1, 2, 
4, 8, 24 h and 7, 14, 28, 60, 90 days post implant. 
Pharmacokinetic analysis of data on the sirolimus 
blood concentration over time was performed 
using the noncompartmental model of Phoenix 
WinNonlin Version 6.3 software (Pharsight Cor-
poration, St. Louis, MO). The only commercially 
available BRS at the time of the study initiation was 
the everolimus-eluting Absorb BVS. Therefore, 
due to a lack of the device eluting the same anti-
proliferative agent (sirolimus) to serve as a direct 
comparator, a control group could not be included 
for the in vivo pharmacokinetic evaluation.
Quantitative coronary angiography 
Quantitative coronary analysis was performed 
using QAngio XA SoftwareTM 7.1.14.0 (Medis 
Medical Imaging System, Leiden, Netherlands). 
The outer diameter of the contrast-filled catheter 
was used as the calibration standard and the mini-
mum lumen diameter (MLD) was obtained from 
the single worst view, while the reference vessel 
diameter (RVD) was automatically calculated by 
the interpolation method. The percent diameter 
stenosis (%DS) was calculated from the MLD and 
the RVD. Acute absolute scaffold recoil was defined 
as the difference between mean diameter of the 
scaffold delivery balloon at the highest pressure 
at implantation (X) and mean luminal diameter of 
stented segment after implantation (Y). Percent 
acute recoil was calculated as (X – Y)/X × 100 [9].
Optical coherence tomography imaging
Optical coherence tomography images were 
recorded using the ILUMIEN PCI Optimization 
System (St. Jude Medical, St. Paul, MN). Motor-
ized OCT pullbacks were performed at a rate of 
20 mm/s. All images were acquired at 100 frames 
per second, displayed with a color look-up table and 
digitally archived. Qualitative and quantitative anal-
yses were performed with the commercial software 
(ILUMIEN OPTIS, St. Jude Medical, St. Paul, MN) 
by an experienced analyst blinded to the device 
information and study methodology, every 1 mm 
within the scaffold segment and including 5 mm of 
the proximal and distal reference segments. The 
following cross-sectional parameters were gener-
ated as previously described [10]: the lumen area, 
the inner and outer scaffold area, percentage area 
of stenosis (%AS) and neointimal thickness (NIT). 
For the purpose of this study lumen area gain was 
calculated as mean lumen area at follow up minus 
mean lumen area at post-implant. Absolute late 
recoil was measured as the mean scaffold diameter 
at post-implant minus the mean scaffold diameter 
at follow-up. Relative late recoil was calculated as: 
(absolute late recoil)/post-implant mean scaffold 
diameter × 100 [11]. Patency ratio was calculated 
as follow-up lumen area/follow-up reference vessel 
area, and its changes were also evaluated at differ-
ent time points. The patency ratio was calculated 
to determine the relationship between the caliber 
of the scaffold-treated vessel region versus the 
caliber of the reference vessel segments proximal 
and distal to the treated region [12]. 
Histological analysis
An independent pathology laboratory (CVPath 
Institute, Gaithersburg, MD) conducted the histo-
pathologic and histomorphometric analysis. Hearts 
were removed immediately following termination 
and the coronary arteries were pressure fixed with 
10% neutral buffered formalin. Treated vessels 
were cut at three in-scaffold levels (proximal, mid, 
distal) and two reference vessel levels. All vessel 
segments were cut twice serially at ~5 microns 
and stained with hematoxylin and eosin and elastin 
trichrome. The resulting slides were examined via 
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light microscopy. The cross-sectional areas delin-
eated by external elastic lamina (EEL), internal 
elastic lamina (IEL) and lumen were measured in 
each section. The neointimal thickness was defined 
as the distance from the inner surface of each strut 
to the luminal border. Neointimal area was defined 
as the difference of IEL area minus lumen area. 
Percentage area of stenosis (%AS) = [1 – (lumen 
area/IEL area)] × 100. Qualitative histological 
assessment on inflammation and healing was per-
formed using a standardized score system [13]. 
Only 9 MeRes-100 and 6 Absorb BVS underwent 
histologic examination in this study.
Definitions
The biomechanical performance endpoint in-
cluded angiographic (MLD, %DS, absolute and per-
cent scaffold recoil), OCT (lumen area, scaffold area, 
neointimal area, %AS, NIT, late lumen gain, absolute 
and relative scaffold recoil) and histomorphometric 
parameters (lumen area, EEL, IEL, NIA, NIT, %AS). 
Biocompatibility evaluation comprised of qualitative 
histological assessment (uncovered struts, neoinitma 
inflammation, adventitia inflammation, fibrin deposi-
tion). Pharmacokinetic evaluation consisted in meas-
uring sirolimus concentration in whole blood and 
arterial tissue at different time intervals.
Statistical analyses 
Statistical analyses was performed using SAS 
statistical software (version 9.4; SAS Institute Inc. 
NC). All measurements were expressed as mean 
± standard deviation. Values were compared be-
tween groups using non-parametric Mann-Whitney 
U tests. The change in continuous outcomes over 
5 time periods (30, 90, 180 days, 1 and 2 years) 
was compared between the two treatment groups 
using analysis of variance (ANOVA) for repeated 
measurements. Post-hoc comparisons were per-
formed using the Scheffe test. The differences 
were considered significant only if the calculated 
p value was < 0.05.
Results
Pharmacokinetic study
Results of the pharmacokinetic analysis are 
summarized in Figure 2. The sirolimus arterial 
tissue concentrations gradually declined over time, 
at 92 days they were about 60% lower than at 30 
days and at 186 days were still detectable yet about 
90% lower than at 30 days (Fig. 2A). The results 
of the sirolimus concentration in whole blood are 
shown in Figure 2B. Peak drug concentrations in 
blood were observed at 1–4 h post implant and 
the average peak concentration of sirolimus was 
7.38 ± 0.42 ng/mL. The blood levels of sirolimus 
quickly declined to below the limit of quantification 
after 14 days.
In vivo study of arterial responses
Quantitative coronary angiography analysis. 
Before injury, the average vessel diameters were 
comparable among both groups (MLD: MeRes-100 
2.55 ± 0.34 mm vs. Absorb BVS 2.62 ± 0.29 mm, 
p = 0.724). Also, the degree of balloon injury 
achieved in all groups was comparable (balloon 
to artery ratio: MeRes-100 1.10 ± 0.11 vs. Ab-
sorb BVS 1.11 ± 0.10, p = 0.893). There were 
no differences in post-implant MLD (MeRes-100 
2.59 ± 0.26 mm vs. Absorb BVS 2.76 ± 0.06 mm, 
p = 0.906). Furthermore, both absolute (MeRes-100 
0.12 ± 0.16 mm vs. Absorb BVS 0.03 ± 0.04 mm, 
p = 0.150) and percentage acute recoil (MeRes-100 
0
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Figure 2. Pharmacokinetic data showing sirolimus release profile (A) sirolimus in whole blood over time (B) sirolimus 
concentrations in the arterial tissue at different time intervals after MeRes-100 bioresorbable scaffolds implantation.
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4.48 ± 5.90% vs. Absorb BVS 1.00 ± 1.43%, 
p = 0.128) were comparable and remained at mini-
mal levels in both groups studied. No post-dilata-
tion was performed in any case. Angiographic data 
at follow-up is summarized in Table 1. At 2 years 
%DS was virtually identical in MeRes-100 when 
compared to Absorb BVS (MeRes-100 20.57 ± 
8.93% vs. Absorb BVS 18.77 ± 11.78%, p = 0.999). 
Late lumen loss, MLD and RVD were comparable 
between groups at all time-points. Representative 
angiographic images over the course of 2 years are 
presented in Figure 3A. 
In vivo OCT analysis. Following device im-
plantation, no differences were observed between 
MeRes-100 and Absorb BVS in terms of lumen or 
reference areas (Table 2). Figure 3B illustrates rep-
resentative OCT images demonstrating the evolu-
tion of the MeRes-100 and Absorb BVS integration 
into the arterial wall and changes in the lumen 
area over time. At 45 days, both scaffolds showed 
a ~30% decrease in lumen area due to neointimal 
proliferation. Thereafter, the average lumen area 
increased again towards the baseline value, which 
was surpassed at 2 years (Fig. 4A). Importantly, in 
both groups studied lumen area increased at a rate 
matching the increase in scaffold area (Fig. 4B). 
Despite small scaffold recoil up to 6 months, the 
beginning of scaffold expansion process was ob-
served starting at 1 year in both MeRes-100 and 
Absorb BVS groups. There were no differences in 
neointimal thickness, neointimal area and %AS 
between MeRes-100 and Absorb BVS at any time-
point. Patency ratio increased ~20% between 1 and 
2 years follow up in both groups (Fig. 4C). 
Histological analysis
A summary of the histological analysis is 
shown in Table 3. Light microscopy revealed that 
vascular responses to MeRes-100 were compa-
rable with those to Absorb BVS at all time points 
(Fig. 5). No significant differences were observed 
in terms of lumen area, %AS or NIT between the 
study groups at 30, 90 or 180 days. The histological 
assessment of biocompatibility and safety variables 
in MeRes-100 and Absorb BVS revealed no differ-
ences at any of the studied time points. Virtually 
all struts were covered in both tested groups at all 
time-points. Neither MeRes-100 nor Absorb BVS 
showed evidence of luminal thrombosis in either 
the main or the side branch of coronary arteries. 
A slight amount of residual fibrin was observed in 
both groups at 30 days that gradually decreased and 
was fully resolved at 180 days. There was numeri-
cally greater neointimal inflammation at all time Ta
b
le
 1
. A
ng
io
gr
ap
hi
c 
o
ut
co
m
es
 a
t f
o
llo
w
 u
p
.
P
o
st
-i
m
p
la
nt
30
 d
ay
s
90
 d
ay
s
18
0 
d
ay
s
1 
ye
ar
2 
ye
ar
P
*
P
 (
in
te
ra
ct
io
n)
R
ef
er
en
ce
 v
es
se
l d
ia
m
et
er
 [
m
m
]
M
eR
es
-1
00
, n
 =
 9
2.
71
 ±
 0
.2
8
2.
60
 ±
 0
.3
4
2.
73
 ±
 0
.3
0
2.
86
 ±
 0
.3
3
3.
05
 ±
 0
.3
6
3.
23
 ±
 0
.3
6
<
 0
.0
01
0.
45
4
A
b
so
rb
 B
V
S
, n
 =
 4
2.
78
 ±
 0
.3
3
2.
68
 ±
 0
.2
0
2.
79
 ±
 0
.3
1
3.
06
 ±
 0
.1
5
3.
37
 ±
 0
.4
8
3.
42
 ±
 0
.4
1
<
 0
.0
01
p
 v
al
ue
#
0.
94
7
0.
99
9
0.
99
9
0.
88
3
0.
46
7
0.
89
1
M
in
im
al
 lu
m
en
 d
ia
m
et
er
 [
m
m
]
M
eR
es
-1
00
, n
 =
 9
2.
59
 ±
 0
.2
6
1.
80
 ±
 0
.3
2
1.
91
 ±
 0
.3
0
1.
95
 ±
 0
.2
2
2.
09
 ±
 0
.2
5
2.
57
 ±
 0
.4
2
<
 0
.0
01
0.
58
8
A
b
so
rb
 B
V
S
, n
 =
 4
2.
76
 ±
 0
.0
6
2.
08
 ±
 0
.2
3
2.
08
 ±
 0
.1
6
2.
27
 ±
 0
.2
1
2.
49
 ±
 0
.2
2
2.
75
 ±
 0
.1
1
<
 0
.0
01
p
 v
al
ue
#
0.
90
6
0.
46
2
0.
89
2
0.
30
6
0.
09
9
0.
86
4
P
er
ce
nt
ag
e 
o
f 
d
ia
m
et
er
 s
te
no
si
s 
[%
]
M
eR
es
-1
00
, n
 =
 9
n/
a
30
.2
8 
±
 1
2.
47
30
.1
3 
±
 7
.1
5
31
.4
2 
±
 7
.4
5
31
.2
5 
±
 7
.3
8
20
.5
7 
±
 8
.9
3
<
 0
.0
01
0.
84
7
A
b
so
rb
 B
V
S
, n
 =
 4
n/
a
22
.5
3 
±
 4
.8
2
25
.1
7 
±
 6
.9
6
24
.5
1 
±
 2
.6
6
25
.3
3 
±
 8
.0
5
18
.7
7 
±
 1
1.
78
<
 0
.0
01
p
 v
al
ue
#
n/
a
0.
52
21
0.
87
4
0.
63
7
0.
76
9
0.
99
9
La
te
 lu
m
en
 lo
ss
 [
m
m
]
M
eR
es
-1
00
, n
 =
 9
n/
a
0.
74
 ±
 0
.4
1
0.
69
 ±
 0
.3
1
0.
64
 ±
 0
.3
2
0.
5 
±
 0
.2
7
0.
04
 ±
 0
.4
5
<
 0
.0
01
0.
65
3
A
b
so
rb
 B
V
S
, n
 =
 4
n/
a
0.
68
 ±
 0
.2
1
0.
68
 ±
 0
.2
2
0.
49
 ±
 0
.2
4
0.
27
 ±
 0
.2
7
0.
01
 ±
 0
.1
6
0.
00
2
p
 v
al
ue
#
n/
a
0.
99
9
0.
99
9
0.
94
5
0.
72
9
0.
99
9
V
al
ue
s 
ar
e 
m
ea
n 
±
 s
ta
nd
ar
d
 d
ev
ia
tio
n;
 *
p
 v
al
ue
 fo
r 
ch
an
ge
 o
ve
r 
tim
e,
 #
p
 v
al
ue
 fo
r 
M
eR
es
-1
00
 v
s.
 A
b
so
rb
 B
V
S
 a
t e
ac
h 
tim
e 
p
o
in
t;
 n
/a
 —
 n
o
t a
p
p
lic
ab
le
www.cardiologyjournal.org 5
Pawel Gasior et al., Preclinical evaluation of a novel thin strut BRS
evidence in the literature that hints at an unfavor-
able peristrut rheology for BVS, as compared with 
metallic stent [15]. Three-dimensional angiographic 
reconstruction techniques and computational fluid 
dynamic data showed low shear stress regions and 
altered flow patterns in-between BVS struts [16]. 
It is known that low endothelial shear stress is 
a powerful local stimulus for atherogenesis, forma-
tion, and progression of an early atherosclerotic 
plaque and differentiation to high-risk plaque [17]. 
Also, ex-vivo porcine arteriovenous shunt model 
and a rabbit model of iliofemoral stent implantation 
demonstrated increased thrombogenicity with re-
spect to platelet aggregation and inflammatory cell 
adhesion in Absorb BVS when compared to thin strut 
biodegradable polymer coated DES [18]. Evidence 
summarized above suggests the necessity in lower-
ing strut thickness without loss of radial strength in 
order to further improve BRS technology [19]. It is 
important to highlight that the novel BRS tested in 
the present study has 100 µm strut thickness (over 
30% less that first generation PLLA-based BRS). 
Furthermore, optimal BRS design should 
ensure not only proper acute lumen gain, but also 
Figure 3. A. Representative angiographic images up to 2 years following scaffold implantation. Both MeRes-100 and 
Absorb demonstrated decrease of stenosis and late lumen gain between 1 and 2 years after implant; B. Representa-
tive images of cross-sectional assessment with optical coherence tomography are shown for MeRes-100 (top panel) 
and Absorb BVS (bottom panel), demonstrating an increase in lumen area between 1 and 2 years after implant. 
A
B
points and especially at 180-days in the MeRes-100 
group, but did not reach statistical significance 
because of the small sample size.
Discussion
In this study, the aim was to evaluate the 
biocompatibility and vascular healing response of 
a novel thin-strut PLLA sirolimus-eluting biore-
sorbable coronary scaffold with hybrid cell design 
compared to the commercially available Absorb 
BVS. The major comparative findings of this study 
in regards to the MeRes-100 are: 1) expansive vas-
cular remodeling starting at 1 year; 2) no in vivo 
scaffold recoil over time; 3) adequate inhibition of 
neointimal proliferation; 4) 6-month healing and 
inflammatory responses was numerically greater 
in MeRes-100 as compared to Absorb BVS.  
Recently a patient-level, pooled meta-analysis 
indicated that target vessel-related myocardial 
infarction was increased with BVS compared with 
DES, due in part to non-significant increases in 
periprocedural myocardial infarction and device 
thrombosis with Absorb BVS [14]. There is also 
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dural biomechanical performance with long-term 
architectural stability compared to Absorb BVS. 
Also being studied were  in vivo changes of the ves-
sel architecture after implantation of the scaffolds 
studied. The data demonstrates that the lumen 
area of reference segments increased over time, 
reflecting normal growth of the animal. Importantly, 
the patency ratio of BRS treated vessels increased 
over time and reached ~0.8 at 2 years follow up 
in both devices (Fig. 4C). This demonstrates that 
Figure 4. A, B. Lumen and scaffold area over the course of 2 years. Both MeRes-100 and Absorb BVS groups dem-
onstrated increases in both parameters over time after the initial decrease at 45 days; C. The patency ratio in both 
groups increased over time starting at 180 days.
sustained lumen patency as the vessel heals. Ex 
vivo degradation and in vivo data of the tested thin 
strut scaffold demonstrates that radial strength is 
decreased by ~50% over 6 months following im-
plantation, which allows complete scaffold resorp-
tion in 2–3 years. Starting at 1-year, an increase 
in scaffold area was observed in both groups up to 
2 years. Then, the in vivo results presented here 
demonstrate that despite significantly lower strut 
thickness MeRes-100 displays similar post-proce-
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both scaffolds studied accommodated natural late 
growth of arteries in this model. 
In vivo pharmacokinetic studies have reported 
that in pig models, systemic peak levels of sirolim-
us reach 2.63 ng/mL at ~1 h after sirolimus-eluting 
stent implantation [20] and by day 29 only 21% of 
the initial sirolimus concentration remained on 
the stent and only minimally detectable systemic 
drug levels were present beyond 7 days [21]. In the 
present study, the peak concentration of sirolimus 
in blood occurred at 1–4 h post implant and the av-
erage of maximum concentration of sirolimus was 
7.38 ± 0.42 ng/mL. The blood levels of sirolimus 
quickly declined to below the limit of quantification 
after 14 days post MeRes-100 implantation. Arte-
rial tissue concentrations gradually declined over 
time and were still detectable 186 days following 
device deployment.  
An important objective of this study was the 
evaluation of vascular healing following the implan-
tation of the novel thin strut BRS. Histology results, 
although limited to 180 days, demonstrated that 
MeRes-100 had comparable healing responses to 
Absorb BVS at all time points, although the lumen 
area was smaller at 30 and 90 days in MeRes-100 
but was similar at 180 days. Whereas, inflamma-
tion was greater in MeRes-100 at all time points, 
especially at 180 days, but the number of implants at 
each time point was inadequate to draw any definite 
conclusions. The slightly higher levels of neointimal 
inflammation seen in the MeRes-100 group at 180 
days are likely related to the degradation process al-
ready underway, which is supposed to be faster than 
that of the Absorb BVS. The levels of fibrin deposits 
in both BRS groups were highest at 1-month. After 
that time point, drug release slows down leading 
to fibrin deposit absorption. Also, there were no 
significant differences in NIT or %AS in the groups 
studied at any time point. These findings suggest 
that MeRes-100 may have the potential to improve 
performance of current generation BRS by providing 
a relatively biocompatible and mechanically durable 
platform at over 30% lower strut thickness than first 
generation PLLA-based BRS.
Limitations of the study
The present study has some limitations that 
are important to note. First, the study was per-
formed in healthy coronary arteries in the swine 
model of restenosis. All scaffolds were implanted 
in the main coronary artery segments avoiding 
large side branches (> 2.0 mm) and the number 
of implants at each time point are too few to draw 
any definite conclusion. The findings cannot predict Ta
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its clinical performance among patients with high 
atherosclerotic burden and especially by lessons 
learnt from ABSORB III clinical trial. However, 
preliminary clinical data with MeRes-100 revealed 
favorable safety and efficacy in a non-randomized 
multicenter first-in-human study [22]. On the other 
hand, some numerical differences between both 
scaffolds might not have reached statistical signifi-
cance due to small sample size. Further, this study 
includes only 30-, 90- and 180-day histological data 
only. The reported study is part of a larger long-term 
biocompatibility study and therefore all the animals 
continued to undergo imaging, and eventually late 
histopathologic follow up. The 30-, 90- and 180-day 
interim data provide a snapshot of the healing profile, 
but long-term histological data are needed.
Conclusions
In conclusion, data herein indicates that 
MeRes-100 scaffold used in the present study 
appeared comparable to control Absorb BVS in 
terms of biomechanical performance and vascular 
healing response up to 180 days, and the OCT 
study up to 2 years in healthy porcine arteries also 
showed similarity to Absorb BVS. Treated arte-
rial segments underwent vascular remodeling in 
parallel with the degradation process of the tested 
polymer scaffolds. Also, pharmacokinetic analysis 
demonstrated the presence of sirolimus in arterial 
tissue 180 days following scaffold implantation. 
The scaffold examined in this preclinical study is 
currently used in clinical studies worldwide, as 
well as being commercially available in select ge-
ographies. Therefore, continuation of its long-term 
preclinical safety and biocompatibility evaluation 
is of paramount clinical importance.
Funding: This study was funded by Meril Life Sci-
ences Pvt. Ltd.
Conflict of interest: None declared
Figure 5. Representative histological images of the MeRes-100 and Absorb BVS in porcine coronary arteries at 
1, 3 and 6 months after implantation.
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